GGH and cancer: In patients with stage II/III gastric cancer who were administrated adjuvant chemotherapy with S-1, although there was no significant difference in the 5-year OS between patients with high and low levels of FPGS mRNA expression, the 5-year OS in patients with the combination of high GGH mRNA and low FPGS mRNA expression levels in cancer tissue was significantly poorer than that in the other patients.